timothy sykes logo

Stock News

Tarsus Pharmaceuticals Adds David Pyott, Boosts Leadership with Allergan Experience

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 2/23/2026, 5:05 pm ET 2/23/2026, 5:05 pm ET | 4 min 4 min read
Tarsus Pharmaceuticals Adds David Pyott, Boosts Leadership with Allergan Experience Thumbnail

Tarsus Pharmaceuticals Inc. stocks have been trading up by 14.8 percent amid optimistic market outlook following positive clinical developments.

Candlestick Chart

Live Update At 17:04:29 EST: On Monday, February 23, 2026 Tarsus Pharmaceuticals Inc. stock [NASDAQ: TARS] is trending up by 14.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tarsus Pharmaceuticals recently saw a significant boost as Goldman Sachs increased the firm’s price target from $51 to $68, a move reflecting growing optimism around the company’s future prospects. The neutral rating, however, suggests some caution remains as investors weigh the potential risks and rewards in this volatile market.

In terms of company performance, recent data shows a varied stock trajectory with TARS peaking at $70.43 on Feb 23, 2026, after experiencing both highs and lows. This fluctuation is indicative of a dynamic market environment, where investors are keeping a keen eye on developments, particularly the anticipated financial report revealing 2025’s Q4 results.

Market Reactions to Tarsus’ Leadership Change

David Pyott, well-acknowledged for his transformative leadership at Allergan, is now part of Tarsus’ board. His experience is expected to spur innovation and strategic growth, particularly in eye care. Pyott’s entry coincides with Tarsus’ commitment to eye-focused health solutions, offering investors a familiar yet invigorating progression in their offerings.

More Breaking News

This move potentially signals to the market an alignment towards strengthening their portfolio, likely resonating well with stakeholders familiar with Allergan’s success story under Pyott’s leadership. Such changes can energize a company’s path forward, hinting at possible strategic partnerships or product launches.

Financial Results Anticipation and Impact

The financial community is eagerly awaiting Tarsus’ full-year 2025 financial results, scheduled to be released on Feb 23, 2026. With FDA-approved XDEMVY for Demodex blepharitis under its belt among other pipeline developments, eyes are drawn toward projected revenues and any strategic insights shared during the webcast.

Financial metrics depict a mixed bag; while the gross margin stands strong at 93.3%, the net income paints a different picture with a loss reported. These figures pose questions about operational efficiency and long-term sustainability—critical points investors will be scrutinizing.

Conclusion

The combination of a raised price target by a financial heavyweight like Goldman Sachs and the strategic onboarding of Pyott portrays a narrative of growth and fortified leadership for Tarsus Pharmaceuticals. While the company’s fundamentals indicate areas requiring further enhancement, their strategic vision under new leadership could prove pivotal in capturing future market opportunities. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” This mindset is crucial as traders consider Tarsus’s potential and how it aligns with broader market trends. As anticipation builds around the impending financial disclosures, Tarsus continues to be a company to watch in the progressing landscape of pharmaceuticals.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”